Biotech Stock to Watch; VIVUS Review
  • Biotech on Watch; Cell Terapeutics plunges on another Dilutive Offering
  • Nasdaq Leader; Vical climbs on Licensing Agreements with Astellas
  • " />

    Biotech Stock Leader: Advanced Cell Technology Review

    Biotech Stock Leader: Advanced Cell Technology Review

    Shares of Advanced Cell Technology Inc. (OTC: ACTC) are continuing to climb in today’s trading after the company yesterday announced that it entered into an agreement with CHA Bio & Diostech Co. Ltd. that will improve the efforts of the two companies’ joint venture. At last check, Advanced Cell Technology shares were trading 3.76% higher at $0.193, with volume at 4.10 million.

    The joint venture between Advanced Cell and South Korea-based CHA is called Stem Cell & Regenerative Medicine International (SCRMI). As per the terms of the agreement, ACT will have exclusive license to SCRMI’s hemangioblast program in North America. CHA will have the exclusive license to the program for Korea and Japan.

    Under the agreement, the SCRMI scientists engaged in hemangioblast research have been reassigned to ACT. The scientists will continue with their research activities as ACT employees.

    The hemangioblast technology developed by SCRMI and ACT is suited for the development of stem cell-based therapies. Robert Lanza, M.D., chief scientist officer of ACT, said that the clinical prospects for the technology are immense. According to Lanza, Hemangioblasts can be used to provide transfusable blood components as well as cells capable of affecting vascular repair. Lanza expects the programs to eventually address the critical care shortage of blood for emergency situations.

    Gary Rabin, interim chairman and CEO of ACT, said that given the progress that has been made by the team at SCRMI and ACT, the new exclusive license affords the company a unique new pipeline of therapeutic products.

     About is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or penny stock market, which has traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them. Disclaimer

    This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly owned subsidiary of BlueWave Advisors.

    While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Leave a Reply

    Your email address will not be published. Required fields are marked *